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Infectious diseases are among the top causes of death in adults and children. Chronic 
diseases such as cardiovascular disease and cancer are among the top causes of death in 
adults. Associations between bacterial and viral infectious agents and subsequent 
development of chronic disease have been made in the past but are currently being re-
examined with more rigor and specificity. This review examines infectious disease agent 
causes and associations with cancer, cardiovascular disease, metabolic disease, and 
neurodegenerative disease. These associations will impact future research, surveillance, 
treatment, and prevention of both infectious and chronic diseases. 
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Introduction	  	  
Infectious diseases represent the second-top cause of death worldwide and are among the top causes 
of death in children under age 5 (Institute of Medicine, 2004; Kochanek, Xu, Murphy, Minino, & 
Kung, 2011). The Institute of Medicine’s report on emerging infections in the United States pointed 
to complacency regarding infectious disease, particularly, emerging infectious diseases and re-
emerging infectious diseases. The report also called for examination of established as well as 
potential relationships between infectious diseases and chronic diseases (Institute of Medicine, 
2004). The Institute of Medicine also argues that a communication gap exists between research, 
public health, and allied health care providers that require further examination. 
Though there have been observed associations between chronic disease and infectious disease since 
the beginning of epidemiological research, increased emphasis on this relationship began in the late 
1970s when new associations between specific infectious and chronic diseases were observed. At that 
time, the assumed cause of peptic ulcers was environmental variables such as chronic stress but was 
alternatively determined to be Helicobacter pylori, an infectious bacterial agent. It is argued that 
this discovery shifted the paradigm relative to causative factors that contribute to chronic health 
conditions and stimulated subsequent research linking infectious and chronic diseases (SoRelle, 
1998).  
Critical also to the consideration of infectious causes of chronic diseases was the advent of genetic 
characterization of organisms using molecular methods in vitro to identify a causal relationship 
(Nelson & Williams, 2007, pg. 482). During this period, epidemiological studies have linked 
infectious agents to cardiovascular disease, cancer, rheumatoid inflammatory disease, and cognitive 
diseases such as dementia and Alzheimer’s disease (Itzhaki, Wozniak, Appelt, & Balin, 2004). 
Considering that the field of epidemiology examines the determinants and distribution of disease in 
communities as well as the application of this data to disease control measures (Aschengrau & 
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Seage, 2008, pg. 6), the objectives of this review include the provision of a brief history of specific 
infectious chronic disease relationships followed by discussion of how these associations have 
impacted or may impact the etiology of the infectious disease. The proposed causative agents; clinical 
aspects of the disease including research findings, associated epidemiology, and prevention; and 
control methods are also outlined for possible infectious causes of cancer, obesity, cardiovascular 
disease, and neurodegenerative diseases. 
Cancer	  
The predominant theory in cancer pathophysiology for the past 50 years has argued that most 
cancers are caused by mutations that dysregulate cellular proliferation in tissues (Ewald, 2009). 
Recently, it has been recognized that infectious agents may be significant initiators of the mutations 
and the dysregulated cellular proliferation that follows (Ewald, 2009), though associations were 
observed as early as 1908 (Calkins) linking an infectious agent not only to cancer but also to the 
growth and proliferation of cancer cells in mice. Ellerman and Bang (1908) also pursued an 
infectious cause for avian leukemia via experimental transfer of the disease between chickens. 
Ochsner (1921) pointed to a de-emphasis among members of the medical profession of the 
relationship between infectious agents and cancer within the context of the public’s perception that 
an association did exist. Mollari and Chinn (1949) pointed to specific etiological relationships 
between viruses and cancer while Epstein (1987) acknowledged 80 years of animal-species-
associated links and argued for emphasis on human infectious agents in their role in subsequent 
development of cancers given that up to 25% of all cancers have a causal or associative viral variable. 
Associations between infectious agents and cancer of the gastrointestinal tract, breast, lung, cervix, 
prostate, and skin support theories that the initial cause of most cancers may be of an infectious 
disease origin (Ewald, 2009). For example, H. pylori was associated with gastric cancer and lymphoid 
tissue lymphoma as early as the 1970s with studies linking Schistosoma haematobium with bladder 
cancer and hepatitis B and C with liver cancer. Human papillomavirus (HPV) is highly associated 
with cervical cancer, and herpes and Kaposi’s sarcoma have also been linked with specific cancer 
types (SoRelle, 1998). 
Hepatitis, initially detected in the 1600s, is a viral infection characterized by inflammation of the 
liver and associated jaundice and gastrointestinal symptoms. In addition to evidence pointing to 
hepatitis as a possible direct cause of inflammation and cellular proliferation in cancer, 
epidemiological evidence finds that populations with high prevalence rates of hepatitis also 
demonstrate high prevalence rates of liver cancer. Further support argues that the United States 
has seen drops in liver cancer since the advent of increased good hygiene habits after the early 
1900s, while developing nations continue to see liver cancer rates unchanged (Hendrickx et al., 
2007).   
Hepatitis B, C, and D are typically transmitted sexually or via exposure to blood. Secondary 
presentation of hepatitis can also occur subsequently to exposure to other viruses such as Ebola. 
Hepatitis is most prevalent in healthcare settings or environments lacking in sanitation and among 
increased-risk groups such as Native Americans and Hispanics, as well as in regions of the world 
such as Africa, Asia, Central and South America, and the Middle East. In addition, individuals with 
frequent and variable sexual partners and intravenous drug users represent an increased risk group. 
Additionally, low socioeconomic status among other variables has been associated with an increased 
prevalence of hepatitis (Nelson & Williams, 2007, pp. 895–939). 
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Regarding worldwide prevalence of hepatitis relative to the United States, though regions previously 
noted (Africa, Asia, Central and South American, Middle East) have higher rates of all forms of 
hepatitis compared with the United States, great variability exists in states and regions in which 
increased-risk residents—such as Native Americans and Hispanics—reside and communities 
characterized by low socioeconomic status. Specifically in the United States, Native Americans are 
three times more likely to be diagnosed with hepatitis, and Hispanics are two times more likely to 
contract the disease compared with Caucasian individuals. In countries outside of the United States 
with highest prevalence rates, up to 80% of children and 90% of adults have been diagnosed with 
hepatitis (Nelson & Williams, 2007, pp. 895–939). 
Hepatitis B is transmitted via blood, and though most infected individuals do not develop chronic 
liver disease, 25% of infants and children who are infected later develop liver cancer. In fact, the link 
of hepatitis B to future development of cancer has driven research and prevention strategies such as 
administration of immunoglobulin and vaccine distribution. Specific increased-risk situations have 
also directed specific prevention strategies such as the prevention of cases contracted during 
childbirth.  As a result, the World Health Organization has added the hepatitis B vaccine to 
children’s scheduled vaccinations (Nelson & Williams, 2007, pp. 895–939). 
It is relevant to note that the association between hepatitis B and C and liver cancer was among the 
first identified associations between infectious disease agents and chronic disease (Choo et al., 1989). 
Subsequent studies revealed that chronic inflammation in the liver produced by hepatitis B and C 
infection caused tissue fibrosis and proliferation of cells. In addition, it has been observed that the 
hepatitis virus also modulates pathways that promote malignancies in liver tissue (Levrero, 2006).  
Hepatitis C infection in the majority of cases does not present acute symptoms; however, when 
symptoms present themselves, they are difficult to distinguish from those associated with other 
hepatitis viruses. Similar to hepatitis B, hepatitis C is transmitted via blood, and as a result, 
individuals with frequent sex partners and intravenous drug users are at increased risk. It is 
estimated that over 170 million individuals are infected with hepatitis C worldwide. Similarly, 
hepatitis C has also been linked to liver cancer (Nelson & Williams, 2007, pp. 895–939). Hepatitis B 
and C infection relative to their relationship to cancer potentiates different courses for prevention. 
Early diagnosis and treatment is argued to be important pursuant to reducing hepatitis-associated 
liver cancer as well as the identification of other risk factors. For example, in individuals who have 
hepatitis B or C, smoking presents an additional risk in the future development of cancer. Alcohol 
consumption is also associated with increased risk of cancer diagnosis post hepatitis infection 
(Hassan et al., 2008). The World Health Organization argues that global surveillance strategies 
(Hendrickx et al., 2007) are likely needed to aid in combating an infectious disease whose forms in 
aggregate affect hundreds of millions of individuals with acute and chronic health implications.  
The epidemiology of hepatitis B and C will be impacted by their association with liver cancer in the 
following ways: Individuals with a history of hepatitis B infection are 60 times more likely to develop 
liver cancer—a more compelling association than established between smoking and lung cancer in 
which smokers are 20–25 times more likely than nonsmokers to develop cancer (Beasley, Lin, 
Hwang, & Chein, 1981). Healthcare and public-health-associated costs for treatment and prevention 
of cancer have doubled in the past 20 years, and cancer diagnoses account for a significant proportion 
of total public health resources (American Cancer Society, 2010). An association or link between 
hepatitis and cancer can impact the epidemiology of hepatitis through collaborated surveillance, 
treatment, and prevention programs in addition to the potential for pooled resources specific to 
funding and research that may result from an established link. Public health and allied health 
professionals are more apt to more aggressively detect and treat hepatitis infection due to a 
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secondary and significant risk of chronic disease. Longitudinal surveillance data in the coming years 
will support or refute a decrease in incidence and prevalence due in part to increased awareness of 
the impact that hepatitis infection has on chronic disease morbidity and mortality. 
Prostate cancer epidemiology is distinguished by several unique factors relative to the proposed role 
of infectious agents in the development of disease. Specifically, prostate cancer incidence rates vary 
widely within the context of location and race with up to a 90-fold difference between African 
Americans living in the United States and males living in Asian countries (Strickler & Goedert, 
2001). Further support for examination into these contrasts is revealed by data that indicates that 
immigration from a low-incidence region to a high-incidence region increases the risk of developing 
prostate cancer fourfold (Strickler & Goedert, 2001). Data finds that differences in sexual behavior in 
African American and Asian males supports an infectious agent association with the development of 
prostate cancer, as males with more sexual partners and a diagnosis of one or more sexually 
transmitted disease are at increased risk of developing cancer (Strickler & Goedert, 2001). 
Specifically, an examination of 250 cases and over 400 controls found that a history of sexually 
transmitted disease was positively associated with prostate cancer (Mandel & Schuman, 1987). 
Similar studies led to examinations of the possibility of an infectious agent’s association with the 
disease.  
Among the first viruses examined in association with prostate cancer were herpes viruses, the 
Epstein-Barr virus, and the Kaposi’s sarcoma virus, which have all been previously associated with 
cancer (Strickler & Goedert, 2001). Subsequent to a failure to find associations with other cancer 
viruses, HPV was examined due to its association with cervical cancer in women with inconclusive 
results (Strickler & Goedert, 2001). More recent studies have associated HPV with 70% of anal 
cancers and precancerous lesions of the penis in men. Cancers of the anus and penis are previously 
rare cancers whose rates have doubled in the past 30 years (Geipert, 2005). 
HPV has been associated with cancer of the cervix in women and is also associated with cancers of 
the head, neck, oral region, and lungs (Spano, Marcelin, & Carcelin, 2005). The prevalence of HPV is 
23% overall in men and women, 35% in 14–19-year-olds, 29% in 20–29-year-olds, 13% in 30–39-year-
olds, and 11% and 6% in men and women 40–49 years of age and over 50 years old, respectively). 
HPV is a sexually transmitted disease with human carriers, wherein the mucosal membrane is the 
site of infection (CDC, 2010b). HPV is also distinguished by an inability to be cultured in vitro, which 
challenges accurate diagnosis. Also confounding accurate diagnosis is the fact that HPV is 
asymptomatic with a varied incubation period between 3 weeks and 8 months. Incidence rates are 
estimated to be as high as 90% in some populations such as young adults. Specific to the etiological 
link to cancer, HPV has been found to cause several changes linked to malignancy and dysregulation 
of tissues of the cervix and other organs. Koilocytosis, a hypertrophy of cervical epithelial cells, is 
accompanied by inflammation and dysplasia. The link of HPV to cancer is also dependent upon 
persistent HPV infection, but within that context, the risk of cervical cancer is over 40 times greater 
compared with uninfected women (Nelson & Williams, 2007, pg. 989). 
H. pylori infection rates worldwide are estimated at 50% of the population with humans representing 
the primary reservoir; however, rates vary greatly according to geographical area, race, 
socioeconomic status, and age. Transmission of H. pylori is through oral-oral or fecal-oral routes via 
contaminated water or soil sources and then transmitted from person to person (Brown, 2000). H. 
pylori is associated with chronic gastritis and gastrointestinal disease in hundreds of epidemiological 
studies, including self-induced case studies involving the researchers infecting themselves to 
demonstrate a causal link to chronic disease. In one case, antibiotics failed to rid the researcher of H. 
pylori, leading to chronic gastric symptoms and complications (Nelson & Williams, 2007, pg. 483). 
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In 1990, it was estimated that 10% of all cancers may have an infectious cause or contributor. For 
example, H. pylori is estimated to be responsible for 5% of all stomach cancers, HPV is estimated to 
be responsible for 5% of cancers of the cervix and vulva, 4% of liver cancers are argued to be 
attributed to Hepatitis, and .5 to 1% of Kaposi’s sarcoma, bladder cancer, leukemia, and 
cholangiocarcinoma are caused by an infectious agent (Nelson & Williams, 2007, pg. 44). More 
recently, HPV was associated with up to 70% of cervical cancer diagnoses (Geipert, 2005). 
An intriguing example of how infectious/chronic diseases associations can affect public health and 
subsequent epidemiology is the direction of clinical trials examining treatments and prevention for 
infectious diseases linked to chronic conditions. For example, HVP infection is associated with 
cervical and vulvar cancer (among others) and women most commonly contract HPV through sexual 
contact with infected male partners. As a result, several clinical trials are examining the effect of 
HPV vaccinations for men and the potential impact on cervical cancer incidence in women (Geipert, 
2005). Recently, a 4-year study has examined the HPV vaccine in men focusing on Latin and South 
American countries where cervical cancer rates are two to three times higher than in the United 
States.. This study divides heterosexual and homosexual men into groups who will be vaccinated and 
compared with matched control subjects. Subsequent tracking of cancer in their partners may lead to 
data pointing to the impact of providing HPV vaccinations to partners for the prevention of HPV and 
cancer (Geipert, 2005). In fact, a recent mathematical population model has estimated the direct and 
indirect public health impact of vaccinating boys and men for HPV. Compared with vaccinating 
females only, the additional decrease in cervical-cancer-associated cases as well as deaths are 
predicted to be over 800,000 within a 100-year period (Elbasha & Dasbach, 2010). 
One caveat produced by epidemiological data is that there is a dramatically different incidence rate 
in the infectious agents with a proposed link to cancer and the cancers themselves. Specifically, the 
rates of all cancers are lower than the rates of the infectious diseases (Morris, Eddleston, & Crook, 
1999). This logically points to likelihood that the infectious causal agent must be combined with 
other variables to initiate cellular proliferation dysfunction (Morris, Eddleston, & Crook, 1999). 
Other challenges relative to surveillance and epidemiology are the varied etiology that is associated 
with each of these interactions as in the relationship between HPV and later development in cancer. 
For example, HPV infection can take between 1 and 10 years to initiate precancerous lesions 
(Moscicki, Schiffman, Kjaer, & Villa, 2006). 
Obesity	  and	  Metabolic	  Disease	  	  
Adenovirus 36 (AD-36) is a moderately sized virus composed of a double-stranded linear DNA 
genome and has been associated with obesity in animal and human case studies and epidemiological 
studies. Adenoviruses in aggregate account for up to 10% of upper respiratory infections in children 
and adults and are spread through droplet or fecal routes. Specific prevention strategies include 
optimal hygiene and sanitation practices and behaviors (Pasarica & Dhurandhar, 2007).  AD-36 was 
first associated with obesity in an examination of chickens (Dhurandhar et al., 2000). Subsequent 
associations between AD-36 and obesity were observed in monkeys, mice, and rats with up to 100% 
of infected animals developing obesity relative to uninfected animals (Salehian et al., 2010). Human 
studies have observed correlations between AD-36 and increased adiposity, including a study that 
found triple the likelihood of obesity in individuals who presented with AD-36 antibodies including a 
mean difference in weight of 25 kg in infected individuals. Twin sibling studies also support an 
association between AD-36 and obesity with infected twins presenting with obesity more frequently 
compared with their uninfected siblings. Human studies have also documented a paradoxical 
decrease in lipid profiles—specifically, observations of lower total cholesterol and low-density 
lipoprotein in AD-36-infected individuals compared with those uninfected (Salehian et al., 2010). 
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The physiological mechanism or causal link between AD-36 and adiposity is the result of gene 
expression changes subsequent to AD-36 infection. Specifically, AD-36 modifies enzymes and 
transcription factors in adipocytes, increasing the binding potential of protein with fatty acid 
synthase. As a result, an increase in transport of lipids into cells is augmented by an increase in 
fatty acid synthesis. The net presentation of inducing enzymes that transport fat and increasing 
adipose tissue is accumulation of excess visceral and subcutaneous fat (Salehian et al., 2010). 
The emergence of AD-36 and its possible association with obesity could significantly impact the 
epidemiology of obesity as we continue to observe increased proportions of obesity in all age groups 
in the United States (Flegal, Carroll, Ogden, & Curtin, 2010). The potential impact on the 
epidemiology of adenoviruses and obesity will alter surveillance, treatment, and prevention 
strategies associated with adenovirus infection and obesity (Whigham, Israel, & Atkinson, 2005). 
Currently, adenoviruses are not routinely tracked, as they typically present with mild or no 
symptoms; however, incident rates of adenovirus among children from 1976 to 2001 indicated 
seasonal patterns and increased infections between January and April and low infection rates during 
the summer months (Nelson & Williams, 2007, pg. 709). It was also found that most individuals 
infected with one type of adenovirus are infected with others, and additionally, it is speculated that 
serotypes other than AD-36 will be associated with obesity (Whigham, Israel, & Atkinson, 2005).  
Relevant to surveillance is the potential need for the identification of increased risk populations for 
AD-36 infection such as individuals living in developing countries, urban environments, and schools 
and health care settings that all present opportunities for droplet transmission illnesses to optimally 
spread. In addition, there will be a potential shift away from the paradigm of associating obesity 
with a chronic disease largely caused by lifestyle factors toward considerations that obesity might 
the result of viral infection (Greenway, 2006). Greenway (2006) argues further that a significant 
proportion of obesity may have a viral cause and supports his argument with the discovery of AD-36 
and the onset of the increase in obesity, both taking place simultaneously. Greenway (2006) also 
argues that additional adenoviruses may contribute to obesity, including AD-37 and AD-5, which are 
being examined in animal studies with similar outcomes to preliminary AD-36 studies using animal 
subjects. Finally, given a potential shift in epidemiology associated with obesity and adenoviruses, it 
is argued that prevention and treatment should consist of screening individuals for AD-36 and the 
redevelopment of a vaccine (Greenway, 2006) that was previously developed for service men and 
women during World War II.  
Metabolic syndrome is characterized by specific limits exceeded for weight, blood glucose, blood 
pressure, and lipid profiles and has been associated with prior infection with Chlamydia pneumoniae 
(CP), H. pylori, cytomegalovirus, and herpes simplex type 1 (HSV 1). Specific odds ratios for the 
development of metabolic syndrome for each are 1.81 for CP, 1.5 for H pylori, 1.69 for 
cytomegalovirus, and 1.95 for herpes for men and women. Though the causative process for these 
relationships have not been established, it is likely that the observed endothelial dysfunction, 
elevated C-reactive protein levels, and chronic subclinical inflammation are contributing to the 
criteria for metabolic disease including hypertension, dyslipidemia, glucose intolerance, and obesity 
(Nabipour, Jafari, Pazoki, & Sanjdideh, 2006). 
Cardiovascular	  Disease	  
Cardiovascular disease (CVD)-related deaths account for the highest proportion of total deaths in the 
United States (CDC, 2011b). Though top risk factors for CVD are largely of a behavioral origin, a 
number of infectious agents have also been associated with increased risk of CVD, including  
H. pylori, cytomegalovirus, periodontal bacteria, and CP. In addition to associations with 
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arthrosclerosis, associations with stroke and peripheral vascular disease have also been explored 
(Larsen, Moern, Fuller, Andersen, & Ostergaard, 2002). CP has also been associated with acute 
myocardial infarction, but these relationships are confounded by CP’s status as an independent risk 
factor for other known and top correlates with CVD, such as smoking and high cholesterol. 
Additional support for a relationship stems from histological studies showing modified lipid 
metabolism following viral infection (Fabricant, 1986) and from associations between viral infections 
and cardiomyopathy, pericardiopathy, and myocarditis (Kawana, 1985). 
Estimated incidence of CP includes 2.5 million cases per year and 500,000 associated 
hospitalizations. Approximately 50% of adults have been infected by age 20 with reinfection likely 
throughout their lifetime). CP is transmitted via droplet respiratory secretions and has been 
associated with asthma, arthritis, and Alzheimer’s disease in addition to CVD (CDC, 2010a). 
The role of CP in CVD is associated with the discovery that individuals who tested positive for the 
immunoglobulin G antibody were at increased risk of later developing a myocardial infarction in 
addition to aggregate evidence from retrospective, prospective, and cross-sectional studies. 
Supporting pathophysiology includes the ability of CP to directly infect cells that constitute 
atheromas, such as coronary artery endothelial cells, macrophages, and aortic smooth muscle cells, 
in addition to promoting intimal lining inflammation and damage (Contini et al., 2009). Studies have 
found double the rate of CP antibody presence in individuals with CVD diagnosis compared with 
individuals with no current CVD. In addition, CP antibodies are essentially absent in cells of arterial 
walls of individuals without CVD (Nelson & Williams, 2007, pg. 486). Dissimilar to several other 
infectious and chronic disease relationships, treatment with antibiotics has not provided attenuation 
of CP infection. Evidence refutes the effectiveness of antibiotic therapy in its prevention of 
subsequent heart attacks (Cercek et al., 2003) in several randomized controlled trials over the short 
and long term (Nelson & Williams, 2007, pg 486). 
Ironically, the association between infectious agents and heart attacks was first proposed in the late 
1800s and persisted through the early 1900s but was replaced by the paradigm and associated 
research linking CVD primarily to behavioral and genetic risk factors (Nelson & Williams, 2007,  
pg. 484). The impact of the association between infectious agents and CVD include modifications to 
treatment and prevention programs that acknowledge this relationship and consider infection a 
viable risk factor for a heart attack. For example, over 5% of physicians in the United States 
recommend including antibiotic treatment for the diagnosis of CVD (Larsen et al., 2002). A study of 
over 200 individuals treated with antibiotics for the prevention of cardiovascular events 
demonstrated a fourfold increase in adverse events in the placebo group, and up to 10 longitudinal 
controlled studies of over 20,000 subjects are currently examining the possible protection provided by 
antibiotics for cardiovascular disease (Larsen et al., 2002). 
Neurodegenerative	  Disease	  
Approximately 5 million Americans have Alzheimer’s disease, with about 5% of men and women over 
65 and 50% of men and women over 85 estimated as having the disease (CDC, 2011a). Behavioral 
risk factors such as high blood pressure, diabetes, high cholesterol, and a sedentary lifestyle are now 
examined within the context of infectious disease agents including CP and HSV 1 infection (Itzhaki 
et al., 2004). CP epidemiology is discussed previously; however in addition to its relatively high 
prevalence in the community, the incubation period associated with CP is longer (several weeks) as 
compared with most other respiratory pathogens, increasing the spread and transmission of the 
disease relative to other respiratory illnesses (Contini et al., 2009). The association between CP and 
neurodegenerative disorders including Alzheimer’s, multiple sclerosis (MS), and neurobehavioral 
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disorders was established via statistical analysis and empirical associations and also due to the 
ability of CP to live and persist in tissues for a long period of time and circumvent the blood-brain 
barrier. CP also activates endothelial cells and causes inflammation, deterioration, and progression 
of the pathophysiology associated with neurodegenerative disease (Itzhaki et al., 2004). For example, 
90% of postmortem brain samples of late onset Alzheimer’s disease victims tested positive for CP 
bacterium (Balin et al., 1998). 
MS is diagnosed in 1–2 individuals per 1000 and is associated with 3000 deaths each year. 
Epidemiological studies suggest that MS is caused by a combination of an infectious agent and 
genetic predisposition. The proposed link between CP and MS is based on the observation that 
modulation of immune activity and “pathogen-associated molecular patterns” is varied depending on 
past CP infection; more compelling, the response is greatest among individuals with multiple past 
CP infections (Itzhaki et al., 2004). Further support associating CP with neurodegenerative disorders 
is the effectiveness of antibiotic treatment in the cases of neurological behavioral disorders, 
encephalitis, Guillan-Barre syndrome, paralysis, aphasia, and neurological sleep disorders (Itzhaki 
et al., 2004). 
HSV 1 virus is not typically transmitted through sexual contact but, alternatively, contracted during 
childhood and presents symptoms including facial lesions. HSV 1 has also been associated with 
genital herpes for specific populations, including residents of developing countries and college 
students in the United States. Overall prevalence of HSV 1 in the United States was 62% between 
the years 1999 and 2004 (Xu, Sternberg, Kottiri, McQuillan, & Lee, 2006). With over 70% of the 
population infected by age 50 and lifelong presence of herpes infection, numerous associations and 
causal links with chronic health conditions are probable (Letenneur et al., 2008). 
HSV 1 has been found to be highly correlated with Alzheimer’s diagnosis. Specifically, a cohort study 
examining over 500 elderly individuals with no diagnosis of Alzheimer’s for 14 years found hazard 
ratios of 2.55 in subjects with previous HSV infection compared with controls (Letenneur et al., 
2008). Unlike CP testing and screening, individuals with HSV 1 infection are more easily and 
accurately detected and, as a result, primary and secondary prevention strategies might be more 
specifically applied. 
Discussion	  and	  Conclusion	  
Public desire to identify a singular cause or “magic bullet” pursuant to chronic diseases can 
potentially hinder the exploration of infectious and chronic causal relationships in several ways. For 
example, the influence of the infectious agent will, in many cases, present similar to other risk 
factors for chronic disease or may play a role as an accelerant to environmental or behavioral risk 
factors. SoRelle (1998) argues that a preemptive conclusion relative to the impact of infectious agents 
may slow epidemiological studies and undermine already established findings. Costs associated with 
researching these associations will be significant as most associations are recently discovered and 
will require long-term controlled studies. For example, a longitudinal study similar to the 
Framingham Study—which has examined CVD epidemiology among three generations of individuals 
since 1948 (National Heart, Lung and Blood Institute and Boston University, 2011)—is proposed to 
analyze the role of infectious agents on chronic diseases (SoRelle, 1998). Data linking infectious 
agents to chronic disease is compelling enough to merit long-term epidemiological studies to 
determine their impact and direct treatment and prevention programs. 
The CDC has responded to emergent infections, re-emergent infections, and potential associations 
between infectious agents and chronic disease with four specific objectives: 
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1. Increasing the rigor associated with surveillance and reporting so that early detection of 
trends or new infections and relationships can be assured  
2. Identifying and supporting applied research activities, including longitudinal studies, 
development of diagnostic tests, and exploring contemporary research areas such as genetics 
and the associations between infectious agents and chronic disease 
3. Strengthening training within the public health system to provide experts in the fields of 
surveillance, program implementation, and assurance roles 
4. Implementing effective treatment and prevention programs that should be directed by and 
be the outcome of the preceding objectives (Hughes, 2001). Known trends in infectious 
disease epidemiology support a need for vigilance in place of complacency due to the 
tendency of microbes to evolve and modify to human demographic and behavior patterns 
(Hughes, 2001). 
Furthermore, the G8 (or Group of Eight industrialized nations) has identified infectious disease as a 
global and national threat to national security with associated goals for reducing HIV infection, 
tuberculosis, and malaria, among other infectious diseases (Hughes, 2001). Recent complacency as 
identified by the Institute of Medicine (2004) and specific gaps in knowledge—as well as 
communication gaps between researchers, public health, and allied health in the United States—are 
critical weaknesses in the area of surveillance, prevention, and control efforts. Increased 
involvement from groups such as the G8 in coordinating these efforts along side the CDC and World 
Health Organization may direct and inform “best practices” associated with surveillance, research, 
and treatment using antibiotics and antiviral medications. 
As previously discussed, the field of epidemiology examines disease distribution and determiners to 
reduce morbidity and mortality (Aschengrau & Seage, 2008, pg. 6). Though there are complexities 
associated with linking viral and bacterial agents to cancer, CVD, cognitive disease, and others, it is 
speculated that the aggregate impact of this emerging topic in infectious disease epidemiology will 
have at least two specific impacts on the epidemiology of infectious disease. Expressly, identification 
of infectious causes of prevalent chronic diseases will likely require research followed by associated 
education, resources, and treatment and prevention programs. Secondly, research examining the 
epidemiology of infectious diseases will increasingly include the possible impact infectious agents 
may have on chronic disease. This will impact the study design of infectious disease research. For 
example, a call for “the Framingham Study of infectious disease” was made in reference to a shift in 
the paradigms associated with infectious and chronic disease epidemiology (SoRelle, 1998). Specific 
to surveillance, it is logical to assume that screening for the infectious agents identified as causes 
will be increased, including screening and testing for currently (and formerly less frequently) tracked 
infectious diseases of a more benign nature and increased screening among suspected cases. For 
example, CP testing may be indicated in the absence of any symptoms, while currently testing for CP 
is not recommended or subject to state or national surveillance or mandatory reporting procedures 
(CDC, 2010a). We may also see resources directed toward screening and detection services.  With 
regards to treatment, thousands of subjects are engaged in infectious-agent-correlative chronic 
disease longitudinal studies at the present time, and many are being managed or treated with 
antibiotics. As a result, subsequent studies are required to determine the effectiveness and prudence 
of antibiotic use for the treatment of chronic diseases given the context of increasing resistance of 
organisms to antibiotics. Caution should be taken when considering increased use of antibiotics for 
the treatment of chronic disease (SoRelle, 1998), and alternate treatment courses may need to be 
determined, such as prevention of infection in place of widespread antibiotic use. For example, 
present and emerging health threats associated with influenza and other infectious diseases with 
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equal or surpassing morbidity and mortality rates compared with chronic diseases may have a 
higher priority relative to antibiotic research and associated treatment. 
Antibiotic use and effectiveness must also be considered within a context of identifying infectious 
disease agents as causes of chronic diseases. Antibiotic treatments for infectious diseases typically 
last weeks in duration, while treatment courses for chronic control of infectious agents can last 
months or years. The impact on microbial resistance is likely to be increased according to current 
studies that monitor antibiotic use and resistance. Specifically, a cross-European study compared 
“high” (32 daily doses per 1000 residents) countries to “low” (10 daily doses per 1000 residents) 
countries and found significantly increased rates of antibiotic resistance in the countries 
administering and consuming the most antibiotics (Goossens, Ferech, Stichele, & Elseviers, 2005). If 
more individuals are prescribed antibiotics for longer treatment courses, it is speculated that the 
aggregate effect on resistance would be increased. In addition, a long-term prevention strategy 
proposed for decreasing microbe resistance has been a reduction in overall antibiotic use, which 
contradicts the proposed increase in prescription and treatments for chronic-disease-associated 
treatment courses of infectious agents. 
An argument for consideration of infectious disease prevalence in healthcare settings may also be 
impacted by aggregate and specific data that points to infectious causes of chronic disease. For 
example, a study linking CP with Alzheimer’s disease found a higher association in skilled nursing 
facilities compared with subjects who lived at home (Contini et al., 2009). Infectious causes of chronic 
illnesses in traditional nosocomial environments may bring more attention to the issue of nosocomial 
infections, which currently account for 2.5 million illnesses and 250,000 associated deaths (Nelson & 
Williams, 2007, pg. 505). 
The Institute of Medicine (2004) characterizes the future of infectious- and chronic-disease-related 
research as facing both challenges and opportunities. Among the challenges are the myriad of ways 
infections interact with other chronic disease variables in acute and chronic manners. High degrees 
of variability are present relative to a viral or bacterial agent’s resistance in the body, degree and 
type of symptoms, and future impact on chronic disease development or acceleration. An inability to 
physically detect or identify the viral or bacterial organism within diseased tissue also presents 
challenges when arguing temporal or associative relationships. Additionally, the mere presence of 
the associative infectious agent will not adequately identify existing or future disease, as other 
behavioral or environmental factors may also need to be present in order for chronic disease to be 
initiated or perpetuated. 
A final consideration permits a discussion of association relative to causation. In several of these 
infectious and chronic causal links, a specific and plausible etiology is proposed or has been 
discovered, such as in the argument for CP and neurodegenerative disease (Itzhaki, 2004). Specific to 
future links that may be proposed, given the prevalence of several of these infectious agents 
approaching or exceeding the majority of the population, it is likely that most individuals will have 
been previously infected by a highly prevalent infectious disease and will later develop a highly 
prevalent chronic disease. In other words, this issue may impact the majority of the population. As a 
result, consideration of the association in isolation is not adequate and must be supported by 
evidence to suggest plausibility and probability that the link is causal in nature, in addition to 
thorough assessment of the costs relative to the heath benefits associated with prevention, screening, 
and treatment. 
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